Clinical Trials Logo

Clinical Trial Summary

Type 2 DM subjects having numbness, tingling and paresthesia in hands and feet (neuropathy) will be recruited. Screening of neuropathy will be done by Michigan screening instrument. This will be followed by nerve conduction studies. Specific blood parameters will also be checked. The subjects will then be divided into four treatment arms. Three groups will receive single drug and the fourth one will receive all the three drugs. These will be given for four months. Follow up will be done every month. At the end of four months, they will be assessed for any improvement in neuropathy by using Michigan neuropathy instrument and nerve conduction studies. Blood parameters will also be measured again.


Clinical Trial Description

Type 2 DM subjects having numbness, tingling and paresthesia in hands and feet (neuropathy) will be recruited. They will be screened by Michigan neuropathy scale. This is tool used for screening neuropathy. Subjects having a score equal to or greater then 4 will be examined for further evaluation. This will be followed by nerve conduction studies for objective assessment of neuropathy. For inclusion criteria the test performed will be HbA1c, CBC, ESR, RFTs and LFTs. After screening the baseline levels of Superoxide radical, Super oxide dismutase, Glutathione peroxidase and Malonaldehyde will be measured. The subjects will be randomly divided into four treatment arms. Group A will receive Triple regime antioxidant therapy including Resveratrol 1500 mg two times a day, Alpha lipoic acid 600 mg two times a day and Superoxide dismutase 250 mg once a day. Group B will receive Resveratrol 1500mg BD, Group C will be on Tab Alpha lipoic acid 600 mg BD and Group D will take Superoxide dismutase once a day. The subjects will be kept blinded about the medication. They will be followed every month in which their quality of life will be assessed using Nottingham health profile and neuropathy will be assessed by Michigan neuropathy scale. At the end of four months blood tests will again be performed to check the levels of Superoxide radical, Superoxide dismutase, Glutathione peroxidase and Malonaldehyde. NCS will be done to see any improvement in neuropathy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06131918
Study type Interventional
Source Khyber Medical University Peshawar
Contact
Status Active, not recruiting
Phase Phase 2
Start date January 9, 2023
Completion date February 20, 2024

See also
  Status Clinical Trial Phase
Completed NCT05491850 - Effects of Moderate Physical Activity on Early Symptoms of Peripheral Diabetic Neuropathy in Type-II Diabetes: A Randomized Clinical Trial N/A
Recruiting NCT04561609 - Transcutaneous Application of Gaseous CO2 N/A
Not yet recruiting NCT06066944 - Effects of Self-Thai Foot Massage on Pain, Range of Motion and Functional Disability in Type 2 DM N/A
Completed NCT03113448 - 0.075% Capsaicin Lotion for the Treatment of Painful Diabetic Neuropathy Phase 3
Completed NCT01293461 - Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes Phase 1/Phase 2